MARKET WIREReuters • 2h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
Why CTOR Stock dropped -8.20% Today — RQD Quant Desk Flash
$0.53 -8.20% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.52
Citius Oncology Inc. (CTOR) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $49.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CTOR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CTOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Citius Oncology Inc. (NASDAQ: CTOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $0.53 (-8.20% 1D, market cap $49.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTOR ranks #679 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CTOR compare to MREO and ATNM in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTOR carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $48.2M) and ATNM (Actinium Pharmaceuticals Inc. (Delaware)) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $48.1M). Among the 5-stock peer group, CTOR leads on earnings multiple (N/A) while CTOR leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CTOR?
▼
Per CTOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001851484), Citius Oncology Inc. generated $0 in revenue, -$24.8M in net income, and -$5.5M in free cash flow against $110.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.52 (-1.67%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTOR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY CTOR SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.84-8.3% Next Q
47
Q2 (-2Q)Grade D$0.77-24.7% Next Q
44
Q3 (-1Q)Grade D$0.58-8.6% Next Q
42
CurrentGrade D-$0.53-7.6% Hist 90D α
39
Trajectory: D (47) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CTOR Turnaround Squeeze
While CTOR currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.84) and Max Pain ($0.56) forces dealer call-delta covering toward $1.92.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTOR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CTOR Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CTOR Stock dropped -8.20% Today — RQD Quant Desk Flash
Citius Oncology Inc. (CTOR) dropped -8.20% to $0.53, trading at 3% of its 52-week range ($0.49 – $1.83). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($0.49 – $1.83) with RSI-14 at 29.1 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.53 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CTOR Headlines & Catalysts
MARKET WIREReuters • 4h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 6h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 6h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 8h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 9h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 10h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 10h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTOR)
- ✓Walkthrough of CTOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CTOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -39.77%▼ SUPPORT BREAKDOWN
2026-10-30O $0.53H $0.56L $0.50C $0.53VOL 291.3K
RES: $1.33SUP: $0.66SMA50: $0.84SMA200: $0.83
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CTOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CTOR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CTOR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CTOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTOR)
Health Care Rank #679 of 1016
⚔️ MREO vs CTOR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CTOR vs. MREO, ATNM, SER, ELTX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Citius Oncology Inc. (CTOR) ranks #679 by composite RQD confidence (39/100, grade D-) and #753 by equity capitalization ($49.2M). Within this direct 5-issuer industry benchmark cohort, CTOR leads on earnings valuation at N/A trailing P/E, while CTOR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SER currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with CTOR at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CTOR
ACTIVE
Citius Oncology Inc. | D- | 39/100 | — | — | -35.0% | -8.20% | $49.2M | Benchmark Subject |
| MREO Mereo BioPharma Group plc | D- | 42/100 | — | — | -35.0% | +1.62% | $48.2M | /mreo-vs-ctor → |
| ATNM Actinium Pharmaceuticals Inc. (Delaware) | D- | 42/100 | — | — | -35.0% | +10.87% | $48.1M | /atnm-vs-ctor → |
| SER Serina Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | +15.24% | $48.0M | /ser-vs-ctor → |
| ELTX Elicio Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -5.40% | $47.4M | /eltx-vs-ctor → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001851484In its most recent audited fiscal period (FY2025, filed 2025-09-30), Citius Oncology Inc. (CTOR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$24.8M, operating cash flow of -$5.5M, and free cash flow of -$5.5M (-4446.6% YoY). On the balance sheet, CTOR closed FY2025 with $110.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $0 | -$24.8M | -$5.5M | -$5.5M | $110.0M | — |
| FY2024 (FY) | 2024-09-30 | $0 | -$21.1M | $126.4K | $126.4K | $90.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | $2.4M | -$601.3K | -$601.3K | — | — |
3. CTOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CTOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Citius Oncology Inc. (NASDAQ: CTOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $0.53 (-8.20% 1D, market cap $49.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTOR ranks #679 in composite RQD confidence.
How does CTOR compare to MREO and ATNM in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTOR carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $48.2M) and ATNM (Actinium Pharmaceuticals Inc. (Delaware)) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $48.1M). Among the 5-stock peer group, CTOR leads on earnings multiple (N/A) while CTOR leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CTOR?
Per CTOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001851484), Citius Oncology Inc. generated $0 in revenue, -$24.8M in net income, and -$5.5M in free cash flow against $110.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CTOR trading relative to its 50-day, 200-day, and 52-week technical levels?
CTOR last traded at $0.53 (-8.20% on volume of 195,085 shares), positioning the stock -36.90% below its 50-day simple moving average ($0.84) and -36.14% below its 200-day simple moving average ($0.83). Across its 52-week range of $0.49 to $1.83, CTOR sits at the 3.0% percentile with a 14-day RSI of 29.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.60).
CTOR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CTOR stock moving today?
Why CTOR Stock dropped -8.20% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.